Together, our study provides a comprehensive insight into the direct relationship among Nrf2 activation, proteinuria, and kidney disease progression in Alport syndrome, and indicates better efficacy of adding a Keap1-Nrf2 PPI inhibitor to ARB. The gene discussed is KEAP1; the disease is Alport syndrome.